Eli Lilly's head of obesity talks weight-loss innovations for 2025 — from an Ozempic-like pill to a triple-threat shot
Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...
Daily2d
Glucagon Sensitivity Similar in Individuals With and Without Type 1 Diabetes: Study Finds
"Overall, metabolic responses to glucagon stimulation in individuals with type 1 diabetes are comparable to those in healthy ...
Healthline8d
How to Get a Zepbound Prescription In Person and Online
Users inject themselves with doses weekly. The active ingredient in Zepbound is tirzepatide. It mimics the hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide ...
pharmaphorum6d
CHMP backs Lilly’s Baqsimi as non-injectable for severe low blood sugar
Baqsimi is a nasal spray formulation of glucagon, already widely used as an injectable treatment for hypoglycaemia, which can occur when people with diabetes inadvertently take too much insulin.
C&EN21h
Weight-loss start-up emerges from stealth
The soaring demand for antidiabetic and weight-loss drugs has lured in many biotech and big Pharma companies. Onto this ...
FiercePharma2d
Gearing up to challenge Lilly in obesity, Kailera picks Zepbound brand leader as new commercial chief
The biotech has named Jamie Coleman its chief commercial officer, per a Monday announcement, putting her in charge of the ...
pharmaphorum2d
After coeliac fail, 9 Meters plots phase 3 in short bowel syndrome
The company is still digging for efficacy signals among subpopulations in the CedLara trial, but has switched its attention to vurolenatide, an injectable glucagon-like peptide-2 (GLP-2 ...